Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Murrell, D. F., Marinovic, B., Caux, F., Prost, C., Ahmed, R., Wozniak, K., Amagai, M., Bauer, J., Beissert, S., Borradori, L., Culton, D., Fairley, J. A., Fivenson, D., Jonkman, M. F., Marinkovich, M. P., Woodley, D., Zone, J., Aoki, V., Bernard, P., Bruckner-Tuderman, L., Cianchini, G., Venning, V., Diaz, L., Eming, R., Grando, S. A., Hall, R. P., Hashimoto, T., Herrero-Gonzalez, J. E., Hertl, M., Joly, P., Karpati, S., Kim, J., Kim, S. C., Korman, N. J., Kowalewski, C., Lee, S. E., Rubenstein, D. R., Sprecher, E., Yancey, K., Zambruno, G., Zillikens, D., Doan, S., Daniel, B. S., Werth, V. P. 2015; 72 (1): 168-174

Abstract

Mucous membrane pemphigoid encompasses a group of autoimmune bullous diseases with a similar phenotype characterized by subepithelial blisters, erosions, and scarring of mucous membranes, skin, or both. Although knowledge about autoimmune bullous disease is increasing, there is often a lack of clear definitions of disease, outcome measures, and therapeutic end points. With clearer definitions and outcome measures, it is possible to directly compare the results and data from various studies using meta-analyses. This consensus statement provides accurate and reproducible definitions for disease extent, activity, outcome measures, end points, and therapeutic response for mucous membrane pemphigoid and proposes a disease extent score, the Mucous Membrane Pemphigoid Disease Area Index.

View details for DOI 10.1016/j.jaad.2014.08.024

View details for PubMedID 25443626